Clarus Corporation (CLAR)
| Market Cap | 918.01M |
| Revenue (ttm) | 289.08M |
| Net Income (ttm) | 15.77M |
| Shares Out | 33.80M |
| EPS (ttm) | 0.48 |
| PE Ratio | 56.38 |
| Forward PE | 17.76 |
| Dividend | $0.08 (0.27%) |
| Ex-Dividend Date | Aug 6, 2021 |
| Volume | 61,373 |
| Open | 26.75 |
| Previous Close | 26.65 |
| Day's Range | 26.75 - 27.63 |
| 52-Week Range | 11.48 - 32.33 |
| Beta | 0.85 |
| Analysts | Strong Buy |
| Price Target | 34.67 (+27.0%) |
| Est. Earnings Date | Nov 8, 2021 |
About CLAR
Clarus Corporation focuses on the outdoor and consumer industries in the United States, Canada, Europe, the Middle East, Asia, Australia, New Zealand, Africa, and South America. The company develops, manufactures, and distributes outdoor equipment and lifestyle products focusing on the climb, ski, mountain, sport, and skincare markets. It operates in two segments, Black Diamond and Sierra. The Black Diamond segment offers activity-based apparel, such as shells, insulation, midlayers, pants, and logowear; rock-climbing footwear and equipment, in...
Financial Performance
In 2020, CLAR's revenue was $224.01 million, a decrease of -2.37% compared to the previous year's $229.44 million. Earnings were $5.55 million, a decrease of -70.77%.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for CLAR stock is "Strong Buy." The 12-month stock price forecast is 34.67, which is an increase of 27.04% from the latest price.
News
Clarus Therapeutics, McGill University Ink Licensing Pact For Rare CoQ10-Associated Conditions
Clarus Therapeutics Holdings Inc (NASDAQ: CRXT) and Canada's McGill University have announced licensing agreement whereby Clarus will develop and commercialize McGill's proprietary technology designed t...
Clarus Sets September 2021 Virtual Conference Schedule
SALT LAKE CITY, UT / ACCESSWIRE / August 30, 2021 / Clarus Corporation (NASDAQ:CLAR) ("Clarus" and/or the "Company"), a global company focused on the outdoor and consumer enthusiast markets, is schedule...
Here's Why Momentum in Clarus Corporation (CLAR) Should Keep going
If you are looking for stocks that are well positioned to maintain their recent uptrend, Clarus Corporation (CLAR) could be a great choice. It is one of the several stocks that passed through our "Recen...
Clarus Corporation (CLAR) Q2 Earnings and Revenues Surpass Estimates
Clarus Corporation (CLAR) delivered earnings and revenue surprises of 5.26% and 17.77%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Clarus Reports Record Second Quarter 2021 Results and Raises Full-Year Outlook
- Sales in the Second Quarter of 2021 Increased 144% Year-Over-Year to a Record $73.3 Million -
Clarus Announces $0.025 Per Share Quarterly Dividend
SALT LAKE CITY, July 30, 2021 (GLOBE NEWSWIRE) -- Clarus Corporation (NASDAQ: CLAR) (“Clarus” and/or the “Company”), a global company focused on the outdoor and consumer enthusiast markets, announced th...
Clarus Earnings Preview
Clarus (NASDAQ:CLAR) will be releasing its next round of earnings this Monday, August 02. For all of the relevant information, here is your guide for Monday's Q2 earnings announcement.
Clarus Corporation (CLAR) Reports Next Week: Wall Street Expects Earnings Growth
Clarus Corporation (CLAR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
7 ‘A-Rated' Small-Cap Stocks to Buy Now
As the economy roars back to life, one of the best places to look for growth is top-quality small-cap stocks that are still bargains. The post 7 ‘A-Rated' Small-Cap Stocks to Buy Now appeared first on I...
Here's Why Momentum in Clarus Corporation (CLAR) Should Keep going
Clarus Corporation (CLAR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Lipocine Stock Jumps On Litigation Settlement With Clarus Therapeutics
Lipocine Inc (NASDAQ: LPCN) has entered into a settlement and license agreement with Clarus Therapeutics to resolve claims in the ongoing intellectual property litigation and interference proceeding. U...
Here's Why Momentum Investors Will Love Clarus Corporation (CLAR)
Does Clarus Corporation (CLAR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Another Summer, Another Deep-Dive into Leisure Stocks
All signs point to a strong leisure market this summer.
Why Clarus Corp (CLAR) Stock Might be a Great Pick
Clarus Corp (CLAR) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.
Top Ranked Momentum Stocks to Buy for July 7th
Top Ranked Momentum Stocks to Buy for July 7th
Clarus Corporation Closes Acquisition of Rhino-Rack
SALT LAKE CITY, July 01, 2021 (GLOBE NEWSWIRE) -- Clarus Corporation (NASDAQ: CLAR) (“Clarus” and/or the “Company”) a global company focused on the outdoor and consumer enthusiast markets, has completed...
Clarus Corporation Upsizes Existing Senior Credit Facility to $225 Million
– Upsized Agreement Features $100 Million Revolving Credit Facility, a $125 Million Term Loan and an Uncommitted $50 Million Accordion – – Upsized Agreement Features $100 Million Revolving Credit Facili...
Here's Why "Trend" Investors Would Love Betting on Clarus Corporation (CLAR)
If you are looking for stocks that are well positioned to maintain their recent uptrend, Clarus Corporation (CLAR) could be a great choice. It is one of the several stocks that passed through our "Recen...
Why You Shouldn't Bet Against Clarus (CLAR) Stock
Clarus (CLAR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Clarus to Acquire Rhino-Rack, Premier Aftermarket Automotive Roof Rack and Accessories Brand
- Transformative Acquisition Aligns with Clarus' Global “Super Fan” Strategy and Expected to Add Significant Scale, Global Reach and Compelling Growth Opportunities -
Clarus Therapeutics Wins Jatenzo Patent Infringement Case Brought By Lipocine
The U.S. District Court for the District of Delaware has granted Clarus Therapeutics' motion for summary judgment against remaining patents in a patent infringement case brought by Lipocine Inc (NASDAQ:...
Clarus (CLAR) Beats on Q1 Earnings & Revenues, Hikes '21 View
Clarus (CLAR) first-quarter 2021 results benefit from robust sales performance from Black Diamond and Sierra.
Clarus Corporation (CLAR) Beats Q1 Earnings and Revenue Estimates
Clarus Corporation (CLAR) delivered earnings and revenue surprises of 29.17% and 7.08%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Clarus: Q1 Earnings Insights
Shares of Clarus (NASDAQ:CLAR) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 244.44% year over year to $0.31, which beat the estimate o...
Clarus Reports Record First Quarter 2021 Results and Raises Full-Year Outlook
- Sales in the First Quarter of 2021 Increase 41% Year-Over-Year to $75.3 Million, Marking Third Consecutive Quarter of Growth -